Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Nat Rev Drug Discov. 2015 Sep 4;14(11):759–780. doi: 10.1038/nrd4593

Figure 5. Combining Therapeutic Strategies to Ameliorate Protein-misfolding / Aggregation Diseases.

Figure 5

We envision that amyloid diseases featuring degenerative phenotypes will be treated in the future using combinations of drugs exhibiting distinct mechanisms of action. For example, we envision treating the TTR amyloidoses with kinetic stabilizers (tafamidis; already in clinical use) and TTR messenger RNA degradation drugs (currently in clinical trials), or using a kinetic stabilizer in combination with drugs that enhance the capacity of the proteostasis network (currently being developed) to achieve proteome maintenance. Given the myriad proteins that lead to aggregation-associated degenerative diseases, strategies such as proteostasis network adaptation that could be useful for multiple maladies are particularly appealing. The goal is to achieve a fully functional proteome without pathogenic amyloidogenicity.